PJP News & Analysis
2 articles
Market Mood
FHLC vs. PJP: Key Healthcare ETFs Show Divergence in Performance
The Fidelity MSCI Health Care Index ETF (FHLC) and Invesco Pharmaceuticals ETF (PJP) provide distinct options for investors, differing in fees, diversification, and returns. FHLC, launched in 2013, holds over 300 stocks and has paid $1.02 per share in dividends over the last year, making it more affordable with a higher yield compared to PJP, launched in 2005, which holds only 33 stocks and paid $1.06 per share in dividends. PJP has outperformed FHLC in both one- and five-year total returns, but its concentrated approach increases risk. Investors focusing on lower costs or income may find FHLC appealing, while those seeking high returns might prefer PJP.
Read More: FHLC vs. PJP: Key Healthcare ETFs Show Divergence in Performance
IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
The iShares U.S. Pharmaceuticals ETF (IHE) has an expense ratio of 0.38% and a dividend yield of 1.62%, while the Invesco Pharmaceuticals ETF (PJP) has a higher expense ratio of 0.57% and a dividend yield of 0.96%. IHE holds 56 positions, heavily concentrated in Eli Lilly (NYSE:LLY) at 24.2% and Johnson & Johnson (NYSE:JNJ) at 20.3%. In contrast, PJP features 29 companies with Eli Lilly at 5.4%. Investors' choice between IHE and PJP hinges on their comfort with company-specific risks within the pharmaceutical sector.
Read More: IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends